Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Biomarkers for Immune Checkpoint Inhibitors Publisher



Sharif PM1, 2 ; Keshavarzfathi M1, 2 ; Rezaei N3, 4, 5
Authors
Show Affiliations
Authors Affiliations
  1. 1. School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Cancer Immunology Project (CIP), Universal Scientific Education and Research Network (USERN), Tehran, Iran
  3. 3. Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  5. 5. Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran

Source: Cancer Immunology: Bench to Bedside Immunotherapy of Cancers# Second Edition Published:2020


Abstract

Since the approval of the first immune checkpoint inhibitor (ICI) for the treatment of melanoma in 2011, this class of agents has undergone various trials and the outcomes have been promising for some patients. However, because of their side effects, limited overall results, and high financial costs, efforts have been made to establish indications so ICIs can be prescribed only for eligible patients. This chapter will review some of the more accepted biomarkers that can differentiate responders to ICIs from the others. Such biomarkers are obtained via different methods, including staining and genomic analysis of tissue biopsies, blood samples, and sometimes stool samples. However, it should be remembered that these biomarkers are not absolute tools for categorizing patients, and presence and/or absence of them in other patients does not always mean that those will not benefit from ICIs. © Springer Nature Switzerland AG 2015, 2021. All rights reserved.
Related Docs
View other Related Docs
1. Tumor Immunology, Clinical Immunology (2022)
2. Biomarkers for Predicting the Outcome of Various Cancer Immunotherapies, Critical Reviews in Oncology/Hematology (2021)
3. Resistance Mechanisms to Programmed Cell Death Protein 1 and Programmed Death Ligand 1 Inhibitors, Expert Opinion on Biological Therapy (2021)
4. Resistance to Immunotherapy in Human Malignancies: Mechanisms, Research Progresses, Challenges, and Opportunities, Journal of Cellular Physiology (2022)
5. Review of the Recent Clinical Trials for Pd-1/Pd-L1 Based Lung Cancer Immunotherapy, Expert Review of Anticancer Therapy (2021)
6. Tumor Immunotherapies by Immune Checkpoint Inhibitors (Icis); the Pros and Cons, Cell Communication and Signaling (2022)
7. Pd-1/Pd-L1 Blockade: Prospectives for Immunotherapy in Cancer and Autoimmunity, IUBMB Life (2021)
8. Recent Advances in Immune Checkpoint Therapy in Non-Small Cell Lung Cancer and Opportunities for Nanoparticle-Based Therapy, European Journal of Pharmacology (2021)
Experts (# of related papers)
View all Related Experts
Nima Rezaei (33)
Hamid Reza Mirzaei (3)
Other Related Docs
9. Cancer Immunotherapy Confers a Global Benefit, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
10. Understanding the Tumor Microenvironment for Effective Immunotherapy, Medicinal Research Reviews (2021)
11. Recent Advances in Non-Small Cell Lung Cancer Targeted Therapy; an Update Review, Cancer Cell International (2023)
12. Pd-1/Pd-L1 Pathway: Basic Biology and Role in Cancer Immunotherapy, Journal of Cellular Physiology (2019)
13. Immune Checkpoint Inhibition for Pancreatic Cancer, Acta Medica Iranica (2023)
14. Immunotherapeutic Targets in Non-Small Cell Lung Cancer, Immunology (2023)
15. Immune Checkpoint Inhibitors: Review of the Existing Evidence and Challenges in Breast Cancer, Immunotherapy (2021)
16. Current and Future Perspectives of Pd-1/Pdl-1 Blockade in Cancer Immunotherapy, Journal of Immunology Research (2021)
17. Cancer Immunology, Encyclopedia of Infection and Immunity (2022)
18. The Evolving Landscape of Predictive Biomarkers in Immuno-Oncology With a Focus on Spatial Technologies, Clinical and Translational Immunology (2020)
19. Immunotherapy a New Hope for Cancer Treatment: A Review, Pakistan Journal of Biological Sciences (2018)
20. Immunotherapeutic Approaches in Cancer, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2019)
21. Hurdles in Cancer Immunotherapy, Cancer Immunology: Bench to Bedside Immunotherapy of Cancers# Second Edition (2020)
22. Immunotherapeutic Approaches in Cancer, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2018)
23. The Tale of Tils in Breast Cancer: A Report From the International Immuno-Oncology Biomarker Working Group, npj Breast Cancer (2021)
24. Immunopathology and Immunotherapy for Breast Cancer, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
25. Immunotherapy of Cancers Comes of Age, Expert Review of Clinical Immunology (2017)
26. Spatial Analyses of Immune Cell Infiltration in Cancer: Current Methods and Future Directions. a Report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer, Journal of Pathology (2023)
27. Immune Checkpoint Inhibitors in Cancer Therapy, Current Oncology (2022)
28. Ctla-4: As an Immunosuppressive Immune Checkpoint in Breast Cancer, Current Molecular Medicine (2023)
29. A Comprehensive Review About the Utilization of Immune Checkpoint Inhibitors and Combination Therapy in Hepatocellular Carcinoma: An Updated Review, Cancer Cell International (2022)
30. The Roles of Cd4+ T-Cells in Tumor Immunity, Cancer Immunology: A Translational Medicine Context# Second Edition (2020)
31. Targeting the Pd-1/Pd-L1 Pathway in Glioblastoma Multiforme: Preclinical Evidence and Clinical Interventions, International Immunopharmacology (2021)
32. Adverse Events Following Administration of Anti-Ctla4 Antibody Ipilimumab, Frontiers in Oncology (2021)
33. Tumor Antigen Identification for Cancer Immunotherapy, Cancer Immunology: Bench to Bedside Immunotherapy of Cancers# Second Edition (2020)
34. Pd-1 and Cancer: Molecular Mechanisms and Polymorphisms, Immunogenetics (2018)
35. Tumor Antigens, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2018)
36. Role of Microbiota-Derived Short-Chain Fatty Acids in Cancer Development and Prevention, Biomedicine and Pharmacotherapy (2021)
37. Evaluation of the Immune Checkpoint Factors in Idiopathic Membranous Nephropathy, Molecular and Cellular Probes (2023)
38. Recent Progress in Cancer Immunotherapy: Overview of Current Status and Challenges, Pathology Research and Practice (2023)
39. Tumor Antigens, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2019)
40. Intestinal Microbiota: Novel Personalized Cancer Immunotherapy in Colorectal Cancer, International Archives of Allergy and Immunology (2022)
41. Impact of Helicobacter Pylori Infection on the Efficacy of Immune Checkpoint Inhibitors for Cancer Treatment: A Meta-Analysis, Immunotherapy (2023)
42. Genetically Modified Immune Cells Targeting Tumor Antigens, Pharmacology and Therapeutics (2020)
43. Development of Neoantigens: From Identification in Cancer Cells to Application in Cancer Vaccines, Expert Review of Vaccines (2022)
44. Immune Checkpoint Inhibitors for Triple-Negative Breast Cancer: From Immunological Mechanisms to Clinical Evidence, International Immunopharmacology (2021)
45. Immune Checkpoint Blockade in Melanoma: Advantages, Shortcomings and Emerging Roles of the Nanoparticles, International Immunopharmacology (2022)
46. Immune Checkpoint Inhibition in Covid-19: Risks and Benefits, Expert Opinion on Biological Therapy (2021)
47. Immune Checkpoint Inhibitors Therapy As the Game-Changing Approach for Pediatric Lymphoma: A Brief Landscape, Critical Reviews in Oncology/Hematology (2024)
48. Gene-Knocked Out Chimeric Antigen Receptor (Car) T Cells: Tuning up for the Next Generation Cancer Immunotherapy, Cancer Letters (2018)
49. Cancer Nanomedicine: Special Focus on Cancer Immunotherapy, Cancer Immunology: Bench to Bedside Immunotherapy of Cancers# Second Edition (2020)
50. Natural Killer Cells and Acute Myeloid Leukemia: Promises and Challenges, Cancer Immunology# Immunotherapy (2022)